A deadly lung disease was discovered in a 68-year-old man during a routine check-up. What seemed…
Continue ReadingTag: IPF
Nerandomilast slows lung function decline in IPF, PPF Clinical trials
Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary…
Continue Reading
Nerandomilast Slows Lung Function Decline in Patients With IPF
Nerandomilast (BI 1015550; Boehringer Ingelheim), an oral phosphodiesterase 4B (PDE4B) inhibitor, significantly slowed lung function decline…
Continue Reading